Investigators

IMV Research Spotlight

Virology Education

Virology Links

Ways to Give

Contact Us

Lectures, Seminars, Meetings & Symposia

News

UMN Virology Timeline

Heather Vezina

Assistant Professor

Department of Laboratory Medicine and Pathology, Medical School

Email: wynnx004@umn.edu
Phone: (612)624-9156

Education

• Pennsylvania University of Pittsburgh, Pittsburgh, PA (1997), B.S. (Pharmacy)
• University at Buffalo, Buffalo, NY (1999), Pharm.D.
• Erie County Medical Center/University at Buffalo, Buffalo, NY (2000), Residency (HIV/ID)
• University of Minnesota, Minneapolis, MN (2002), Fellowship (Clinical Pharmacology)

Research Interests

Antiviral clinical pharmacology with a specific interest in antiretroviral agents.

Selected Recent Publications

• Esch, L., Hardy, H., Wynn, H.E., Shelton, M.J., Hewitt, R.G., and Morse, G.D., Pharmacist-coordinated adherence enhancement program improves virologic response to highly active antiretroviral therapy, Annual Meeting of the American College of Clinical Pharmacy, Kansas City, MO. October 24 - 27, 1999.
• Esch, L., Hardy, H., Wynn, H.E., and Shelton, M.J., Discrepancy between patient-reported adherence and pharmacist-assessed adherence to antiretroviral therapy in patients with human immunodeficiency virus infection, Annual Meeting of the American College of Clinical Pharmacy, Los Angeles, CA. November 5 - 8, 2000.
• Shelton, M.J., Wynn, H.E., Hewitt, R.G., and Difrancesco, R., Effects of grapefruit jutce on pharmacokinetic exposure to indinavir in HIV-positive subjects, J Clin Pharmacol, 41:435-442, 2001.
• Shelton, M.J., Wynn, H.E., Scott, J., and Hewitt, R.G., Risk of amprenavir rash in HIV patients with prior exposure to sulfonamides, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL. December 16 - 19, 2001.
• Raynor, C., Esch, L., Wynn, H.E., and Eales, R., Symptomatic hyperbilirubinemia after the addition of ritonavir to an indinavir-containing regimen, Pharmacotherapy, 35:1391-1395, 2001.
• Esch, L., Hardy, H., Wynn, H.E., Shelton, M.J., Hewitt, R.G., and Morse, G.D., Intensive adherence interventions improve virologic response to antiretroviral therapy (ART) in naive patients, 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL. February 4 - 8, 2001,
• Fletcher, C.V., Anderson, P.L., Kakuda, T.N., Hellman, N., Wynn, H.E., and Brundage, R.C., Anovel approach to integrate pharmacologic and virologic characteristics: an in vivo potency (IVP) index for antiretroviral therapy, 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL. February 4 - 8, 2001.
• Wynn, H.E., Anderson, P.L., and Fletcher, C.V., Pharmacokinetic characteristics of protease inhibitor-based salvage antiretroviral treatment regimens, Annual Meeting of the American College of Clinical Pharmacy, Albuquerque, NM. October 20 - 23, 2002.
• Wynn, H.E., Brundage, R.C., and Fletcher, C.V., Clinical implications of CNS penetration of antiretrovirals, CNS Drugs, 16(9):595-609, 2002.
• Wynn Vezina, H.E., Brundage, R.C., Bushman, L., and Fletcher, C.V., Pharmacologic management of the drug-drug interaction between lopinavir/ritonavir (LPV/r) and amprenavir (APV), 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA. February 8 - 11, 2004.
• Hermsen E.D., Wynn H.E., and McNabb J., Discontinuation of prophylaxis for HIV-associated opportunistic infections in the era of highly active antiretroviral therapy, Am J Health Syst Pharm, 61(3):245-56, 2004.
• King, J.R., Wynn, H.E., Brundage, R.C., and Acosta, E.P. Pharmacokinetic enhancement of protease inhibitor therapy, Clin Pharmacokinet, 43(5):291-310, 2004.
• Wynn Vezina, H.E., Henry, K., Ravindran, G.D., Kurpad, A.V., Raj, T.D.S., Fox, K., Weller, D., Brundage, R.C., Bromander, R., Cavert, W., and Balfour Jr., H.H., International bioequivalence study of generic and brand formulations of nevirapine, zidovudine and lamivudine, 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA. February 22 - 25, 2005.